Advanced Non-Small Cell Squamous Lung Cancer, Immunotherapy, Radiotherapy
Conditions
Keywords
omitting CTV
Brief summary
The aim of this randomized study is to investigate pneumonitis, local tumor control, and survival outcomes of primary tumor radiotherapy omitting CTV for patients with advanced NSCLC responded to immunotherapy and chemotherapy
Detailed description
Studies have confirmed that systemic therapy combined with primary tumor radiotherapy can improve symptoms and prolong survival of advanced NSCLC. Our previous sturdy indicated that patients who received immunotherapy and subsequent radiotherapy suffered higher proportion of pneumonitis. Patients suffered grade 2 or more pneumonitis have worse prognosis. It is urged to optimize the radiotherapy dose and target volume for patients treated with immunotherapy and radiotherapy. According to retrospective and prospective studies, omitting primary tumor CTV radiation therapy showed no reduction in local control and survival for locally advanced NSCLC. It is postulated that omitting CTV radiation for patients responded to therapy with immunotherapy and chemotherapy will have less pneumonitis without sacrificing the local control rate. Omitting CTV may also retain better immune function which will facilitate the immunotherapy.
Interventions
RADIATIONCTV omitted or delineated
Patients who responded to the therapy (immunotherapy and chemotherapy) were randomly (1:1) assigned into CTV-omitted radiotherapy group or CTV-delineated radiotherapy group.
Sponsors
Hubei Cancer Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Histologically or cytologically confirmed advanced non-small cell lung cancer (according to the 8th edition of the TNM cancer staging system of AJCC and UICC); 2. After over two cycles of chemotherapy combined with immunotherapy, the efficacy was CR, PR or SD (with a decreasing trend); 3. Age 18 to 80 years old, performance status 0-1; 4. measurable or evaluable lesions; 5. Survival expectancy is not less than 6 months; 6. adequate cardiac, pulmonary, renal, and hepatic and bone marrow function
Exclusion criteria
1. tumor progress after therapy with immunotherapy and chemotherapy 2. EGFR, ALK, or ROS1 mutation; 3. Previous thoracic radiotherapy; 4. grade 2 or more immune-related adverse events after induction immunotherapy 5. Previous malignancies (except stage I non-melanic skin cancer or cervical carcinoma in situ); 6. Pregnant or lactating women 7. undergoing other clinical trials; 8. Have serious comorbidities, including myocardial infarction, severe arrhythmia, severe cerebrovascular disease, ulcer disease, psychosis and uncontrollable diabetes; 9. Patients with HIV positive and undergoing antiviral therapy; 10. Active tuberculosis
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| grade 2 or more pneumonitis | up to 6 months |
Secondary
| Measure | Time frame |
|---|---|
| local/regional control rate | up to 12 months |
| Progress free survival | up to 12 months |
| grade 3 or more pneumonitis | up to 6 months |
| grade 3 or more esophagitis | up to 6 months |
Countries
China
Contacts
Primary ContactGuang Han, PhD
Outcome results
None listed